Salute e Benessere
LUPKYNIS Strengthens Market Position as Demand for Lupus Nephritis Treatment Grows | DelveInsight
LUPKYNIS (voclosporin) is an oral immunosuppressant classified as a calcineurin inhibitor (CNI), shown to improve both short- and long-term outcomes in adult patients with active lupus nephritis when used alongside standard immunosuppressive therapies. By targeting calcineurin, LUPKYNIS helps suppress cytokine activity, inhibits interleukin-2 (IL-2) production, and reduces T-cell driven immune responses.
Although the exact mechanism by which voclosporin inhibits calcineurin is not fully understood, it is known that lymphocyte activation increases intracellular calcium, which binds to calcineurin's regulatory site. This activates the calmodulin-binding catalytic subunit, leading to dephosphorylation and activation of the transcription factor NFATc (nuclear factor of activated T-cells, cytoplasmic). The drug's immunosuppressive effect results in decreased lymphocyte proliferation, reduced cytokine production, and lower expression of T-cell activation markers.
The recommended initial dose of LUPKYNIS is 23.7 mg twice daily. It should be used in conjunction with mycophenolate mofetil (MMF) and corticosteroids.
Learn more about LUPKYNIS projected market size for lupus nephritis @
Lupus nephritis is a serious and potentially life-threatening complication of systemic lupus erythematosus (SLE), affecting of those diagnosed with the disease. It is typically characterized by symptoms such as hematuria (blood in the urine) and proteinuria (protein in the urine). This condition is more prevalent in women, particularly between the ages of 20 and 40. In 2023, the United States recorded the highest number of lupus nephritis cases among the 7MM, with approximately cases, a figure projected to grow by 2034.
Treatment strategies for lupus nephritis depend on the kidney biopsy classification of the disease. Standard therapy often includes corticosteroids in combination with immunosuppressive drugs like cyclophosphamide, mycophenolate mofetil, azathioprine, and calcineurin inhibitors. Rituximab, a monoclonal antibody, is widely used, especially for patients with relapsing or treatment-resistant LN, due to its ability to reduce reliance on steroids.
Currently, there are only two FDA-approved medications for lupus nephritis: , available as an intravenous or subcutaneous formulation, and , a novel oral calcineurin inhibitor.
Leading pharmaceutical companies such as among others, are actively developing innovative therapies that could redefine the treatment paradigm for lupus nephritis. The treatment landscape is rapidly evolving, shifting away from broad immunosuppression toward more precise, targeted approaches. Recent drug approvals and a strong pipeline of candidates highlight both advancements and the ongoing challenges in creating treatments that are effective, safe, and long-lasting.
Emerging therapies ranging from anti-CD20 antibodies and complement inhibitors to interferon-blocking agents and CAR-T cell therapies hold promise but must address key issues such as safety, sustained efficacy, and accessibility. As our understanding of the disease's underlying mechanisms continues to grow, the future of lupus nephritis treatment is expected to become increasingly personalized, offering renewed hope to patients battling this complex disorder.
Discover more about the lupus nephritis market in detail @
The developing pipeline for lupus nephritis treatments shows a growing variety of approaches. Multiple candidates, both in early and late stages of development, are underway, including (Novartis), (Roche), (AstraZeneca), (Novartis), (AstraZeneca), as well as advanced cellular therapies like (Cabaletta Bio) and (Novartis).
In the FDA accepted a supplemental Biologics License Application based on data from the , where obinutuzumab demonstrated a 46.4% Complete Renal Response (CRR), compared to 33.1% for placebo. Unlike previous anti-CD20 therapies such as rituximab, it provides enhanced B-cell depletion and is the first in its class to show efficacy in a randomized Phase III lupus nephritis trial. If approved, it will become the first CD20-targeted treatment specifically indicated for lupus nephritis, with anticipated sales of by 2034.
To know more about the number of competing drugs in development, visit @
Discover how LUPKYNIS is shaping the lupus nephritis treatment landscape @
LUPKYNIS, developed by Aurinia Pharmaceuticals, is the specifically indicated for active lupus nephritis, a serious manifestation of systemic lupus erythematosus. Approved in
January 2021 in the US, LUPKYNIS entered a where treatment was largely dependent on off-label use of immunosuppressants like mycophenolate mofetil and corticosteroids. The drug represents a significant advancement in lupus nephritis care, offering both compared to existing options, especially in reducing proteinuria and preserving kidney function.
The market dynamics for LUPKYNIS are shaped by several key factors. On the positive side, there is a , and about early diagnosis and intervention. Moreover, LUPKYNIS benefits from a , supported by its novel mechanism and disease-modifying potential. Aurinia has also built a to drive uptake and adherence.
However, LUPKYNIS faces . One of the main competitors is , which gained FDA approval for lupus nephritis in December 2020 , just a month before LUPKYNIS. Benlysta has the advantage of brand recognition and a longer track record in treating systemic lupus. Additionally, payers have shown some hesitancy in approving LUPKYNIS due to its cost, requiring . Patient compliance also remains an issue, given the need for frequent monitoring of kidney function and drug levels.
Looking ahead, the market potential for LUPKYNIS will depend on its , and . Aurinia is also exploring lifecycle management strategies, including combination therapies and expanded indications. could further boost market access and penetration. Overall, while LUPKYNIS is a pioneering therapy with strong clinical value, its commercial success will be defined by navigating payer landscapes, physician adoption, and sustained differentiation from competing therapies.
Dive deeper to get more insight into LUPKYNIS's strengths & weaknesses relative to competitors @
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key lupus nephritis companies, including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key lupus nephritis companies, including among others.
report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key SLE companies, including among others.
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key myasthenia gravis companies, including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/lupkynis-strengthens-market-position-as-demand-for-lupus-nephritis-treatment-grows--delveinsight-302449679.html